Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Susmitha Ambadipudi & Markus Zweckstetter. (2016) Targeting intrinsically disordered proteins in rational drug discovery. Expert Opinion on Drug Discovery 11:1, pages 65-77.
Read now
Read now
Francesco Panza, Vincenzo Solfrizzi, Bruno P Imbimbo, Michele Giannini, Andrea Santamato, Davide Seripa & Giancarlo Logroscino. (2014) Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease. Expert Review of Neurotherapeutics 14:9, pages 973-986.
Read now
Read now
Francesco Panza, Vincenzo Solfrizzi, Bruno P Imbimbo, Rosanna Tortelli, Andrea Santamato & Giancarlo Logroscino. (2014) Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Review of Clinical Immunology 10:3, pages 405-419.
Read now
Read now
Geovanny Rivera-Hernández, Marta Marín-Argany, Bernat Blasco-Moreno, Jaume Bonet, Baldomero Oliva & Sandra Villegas. (2013) Elongation of the C-terminal domain of an anti-amyloid β single-chain variable fragment increases its thermodynamic stability and decreases its aggregation tendency. mAbs 5:5, pages 678-689.
Read now
Read now
Bared Safieh-Garabedian, Yunis Mayasi & Nayef E Saadé. (2012) Targeting neuroinflammation for therapeutic intervention in neurodegenerative pathologies: a role for the peptide analogue of thymulin (PAT). Expert Opinion on Therapeutic Targets 16:11, pages 1065-1073.
Read now
Read now
Kelly R Bales. (2012) The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update. Expert Opinion on Drug Discovery 7:4, pages 281-297.
Read now
Read now
Bruno P Imbimbo, Simone Ottonello, Vincenza Frisardi, Vincenzo Solfrizzi, Antonio Greco, Davide Seripa, Alberto Pilotto & Francesco Panza. (2012) Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease. Expert Review of Clinical Immunology 8:2, pages 135-149.
Read now
Read now
Articles from other publishers (40)
Milad Zangiabadi, Avijit Ghosh & Yan Zhao. (2023) Nanoparticle Scanners for the Identification of Key Sequences Involved in the Assembly and Disassembly of β-Amyloid Peptides. ACS Nano 17:5, pages 4764-4774.
Crossref
Crossref
Parth Sharma, Ritchu Babbar, Twinkle Sharma, Piyush Madaan, Sandeep Arora & Vishnu Nayak Badavath. (2023) Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's
Disease. Mini-Reviews in Medicinal Chemistry 23:1, pages 53-66.
Crossref
Crossref
Jeffrey Cummings, Jefferson Kinney & Howard Fillit. 2022. Alzheimer's Disease Drug Development. Alzheimer's Disease Drug Development
1
24
.
Shilpa Sharma, Priya Modi, Gargi Sharma & Shashank Deep. (2021) Kinetics theories to understand the mechanism of aggregation of a protein and to design strategies for its inhibition. Biophysical Chemistry 278, pages 106665.
Crossref
Crossref
Parveen Salahuddin, Rizwan Hasan Khan, Mohammad Furkan, Vladimir N. Uversky, Zeyaul Islam & Munazza Tamkeen Fatima. (2021) Mechanisms of amyloid proteins aggregation and their inhibition by antibodies, small molecule inhibitors, nano-particles and nano-bodies. International Journal of Biological Macromolecules 186, pages 580-590.
Crossref
Crossref
Md. Tanvir Kabir, Md. Sahab Uddin, Philippe Jeandet, Talha Bin Emran, Saikat Mitra, Ghadeer M. Albadrani, Amany A. Sayed, Mohamed M. Abdel-Daim & Jesus Simal-Gandara. (2021) Anti-Alzheimer’s Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential. Marine Drugs 19:5, pages 251.
Crossref
Crossref
Steven S. Plotkin & Neil R. Cashman. (2020) Passive immunotherapies targeting Aβ and tau in Alzheimer's disease. Neurobiology of Disease 144, pages 105010.
Crossref
Crossref
Pei Ying Ng, I Shuen Chang, Rhun Yian Koh & Soi Moi Chye. (2020) Recent advances in tau-directed immunotherapy against Alzheimer’s disease: an overview of pre-clinical and clinical development. Metabolic Brain Disease 35:7, pages 1049-1066.
Crossref
Crossref
Somin Kwon, Michiyo Iba, Changyoun Kim & Eliezer Masliah. (2020) Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets. Neurotherapeutics 17:3, pages 935-954.
Crossref
Crossref
Jinbing Xie, Daniel Gonzalez-Carter, Theofilus A. Tockary, Noriko Nakamura, Yonger Xue, Makoto Nakakido, Hiroki Akiba, Anjaneyulu Dirisala, Xueying Liu, Kazuko Toh, Tao Yang, Zengtao Wang, Shigeto Fukushima, Junjie Li, Sabina Quader, Kouhei Tsumoto, Takanori Yokota, Yasutaka Anraku & Kazunori Kataoka. (2020) Dual-Sensitive Nanomicelles Enhancing Systemic Delivery of Therapeutically Active Antibodies Specifically into the Brain. ACS Nano 14:6, pages 6729-6742.
Crossref
Crossref
Allal Boutajangout, Hanna Lindberg, Abdulaziz Awwad, Arun Paul, Rabaa Baitalmal, Ismail Almokyad, Ingmarie Höidén-Guthenberg, Elin Gunneriusson, Fredrik Y. Frejd, Torleif Härd, John Löfblom, Stefan Ståhl & Thomas Wisniewski. (2019) Affibody-Mediated Sequestration of Amyloid β Demonstrates Preventive Efficacy in a Transgenic Alzheimer’s Disease Mouse Model. Frontiers in Aging Neuroscience 11.
Crossref
Crossref
Jason Pitt. 2019. Biomarkers in Toxicology. Biomarkers in Toxicology
885
894
.
Steven Hoover & Mary Sano. 2019. Handbook on the Neuropsychology of Aging and Dementia. Handbook on the Neuropsychology of Aging and Dementia
335
353
.
Kewal K. JainKewal K. Jain. 2019. The Handbook of Neuroprotection. The Handbook of Neuroprotection
465
585
.
Jeffrey Cummings, Aaron Ritter & Kate Zhong. (2018) Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future. Journal of Alzheimer's Disease 64:s1, pages S3-S22.
Crossref
Crossref
Pravas Kumar Baral, Mridula Swayampakula, Adriano Aguzzi & Michael N. G. James. (2018)
Structural characterization of
POM
6 Fab and mouse prion protein complex identifies key regions for prions conformational conversion
. The FEBS Journal 285:9, pages 1701-1714.
Crossref
Crossref
D’Artagnan Greene, Theodora Po, Jennifer Pan, Tanya Tabibian & Ray Luo. (2018) Computational Analysis for the Rational Design of Anti-Amyloid Beta (Aβ) Antibodies. The Journal of Physical Chemistry B 122:16, pages 4521-4536.
Crossref
Crossref
Das Bhaskar C. (2018) The Role of Tau Protein in Diseases. Annals of Advances in Chemistry, pages 001-016.
Crossref
Crossref
Nuzhat Ahsan, Ibrar Ahmed Siddique, Sarika Gupta & Avadhesha Surolia. (2018) A routinely used protein staining dye acts as an inhibitor of wild type and mutant alpha-synuclein aggregation and modulator of neurotoxicity. European Journal of Medicinal Chemistry 143, pages 1174-1184.
Crossref
Crossref
Leah K. Cuddy, Claudia Seah, Stephen H. Pasternak & R. Jane Rylett. (2017) Amino-Terminal β-Amyloid Antibody Blocks β-Amyloid-Mediated Inhibition of the High-Affinity Choline Transporter CHT. Frontiers in Molecular Neuroscience 10.
Crossref
Crossref
Francesco A. AprilePietro SormanniMichele PerniPaolo ArosioSara Linse, Tuomas P. J. KnowlesChristopher M. DobsonMichele Vendruscolo. (2017) Selective targeting of primary and secondary nucleation pathways in Aβ42 aggregation using a rational antibody scanning method. Science Advances 3:6.
Crossref
Crossref
Tara P. Hurst, Caroline Coleman-Vaughan, Indu Patwal & Justin V. McCarthy. (2016) Regulated intramembrane proteolysis, innate immunity and therapeutic targets in Alzheimer’s disease. AIMS Molecular Science 3:2, pages 138-157.
Crossref
Crossref
Lenka Hromadkova, Michala Kolarova, Barbora Jankovicova, Ales Bartos, Jan Ricny, Zuzana Bilkova & Daniela Ripova. (2015) Identification and characterization of natural antibodies against tau protein in an intravenous immunoglobulin product. Journal of Neuroimmunology 289, pages 121-129.
Crossref
Crossref
Paul J. Lucassen, Edwin H. Jacobs, Lianne Hoeijmakers, Sylvie Lesuis, Harm Krugers, Aniko Korosi, H. Georg Kuhn & Karin Boekhoorn. 2015. Neural Stem Cells in Development, Adulthood and Disease. Neural Stem Cells in Development, Adulthood and Disease
53
78
.
Francesco Panza, Giancarlo Logroscino, Bruno P. Imbimbo & Vincenzo Solfrizzi. (2014) Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?. Current Opinion in Psychiatry 27:2, pages 128-137.
Crossref
Crossref
Paolo Arosio, Michele Vendruscolo, Christopher M. Dobson & Tuomas P.J. Knowles. (2014) Chemical kinetics for drug discovery to combat protein aggregation diseases. Trends in Pharmacological Sciences 35:3, pages 127-135.
Crossref
Crossref
Jason Pitt. 2014. Biomarkers in Toxicology. Biomarkers in Toxicology
801
815
.
Elvira Valera & Eliezer Masliah. (2013) Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies. Pharmacology & Therapeutics 138:3, pages 311-322.
Crossref
Crossref
Susann Cattepoel, Alexander Schaub, Miriam Ender, Annette Gaida, Alain Kropf, Ursula Guggisberg, Marc W. Nolte, Louis Fabri, Paul A. Adlard, David I. Finkelstein, Reinhard Bolli & Sylvia M. Miescher. (2013) Intravenous Immunglobulin Binds Beta Amyloid and Modifies Its Aggregation, Neurotoxicity and Microglial Phagocytosis In Vitro. PLoS ONE 8:5, pages e63162.
Crossref
Crossref
Alex E. Roher, David H. Cribbs, Ronald C. Kim, Chera L. Maarouf, Charisse M. Whiteside, Tyler A. Kokjohn, Ian D. Daugs, Elizabeth Head, Carolyn Liebsack, Geidy Serrano, Christine Belden, Marwan N. Sabbagh & Thomas G. Beach. (2013) Bapineuzumab Alters A? Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy. PLoS ONE 8:3, pages e59735.
Crossref
Crossref
Elias Akoury, Michal Gajda, Marcus Pickhardt, Jacek Biernat, Pornsuwan Soraya, Christian Griesinger, Eckhard Mandelkow & Markus Zweckstetter. (2013) Inhibition of Tau Filament Formation by Conformational Modulation. Journal of the American Chemical Society 135:7, pages 2853-2862.
Crossref
Crossref
Jeffrey A. Rumbaugh, Muznabanu Bachani, Wenxue Li, Tracy R. Butler, Katherine J. Smith, Mario A. Bianchet, Tongguang Wang, Mark A. Prendergast, Ned Sacktor & Avindra Nath. (2013) HIV immune complexes prevent excitotoxicity by interaction with NMDA receptors. Neurobiology of Disease 49, pages 169-176.
Crossref
Crossref
Steven Hoover & Mary Sano. 2013. Handbook on the Neuropsychology of Aging and Dementia. Handbook on the Neuropsychology of Aging and Dementia
59
77
.
Ronald B. DeMattos, Jirong Lu, Ying Tang, Margaret M. Racke, Cindy A. DeLong, John A. Tzaferis, Justin T. Hole, Beth M. Forster, Peter C. McDonnell, Feng Liu, Robert D. Kinley, William H. Jordan & Michael L. Hutton. (2012) A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice. Neuron 76:5, pages 908-920.
Crossref
Crossref
Thomas Appl, Linda Kaltenbach, Donald C. Lo & Georg C. Terstappen. (2012) Targeting mutant huntingtin for the development of disease-modifying therapy. Drug Discovery Today 17:21-22, pages 1217-1223.
Crossref
Crossref
Damien Hall & Herman Edskes. (2012) Computational modeling of the relationship between amyloid and disease. Biophysical Reviews 4:3, pages 205-222.
Crossref
Crossref
Torleif Härd & Christofer Lendel. (2012) Inhibition of Amyloid Formation. Journal of Molecular Biology 421:4-5, pages 441-465.
Crossref
Crossref
Zhiping Zhang, Tom Goldschmidt & Hugh Salter. (2012) Possible allelic structure of IgG2a and IgG2c in mice. Molecular Immunology 50:3, pages 169-171.
Crossref
Crossref
Francesco PanzaVincenza Frisardi, Vincenzo Solfrizzi, Bruno P Imbimbo, Giancarlo Logroscino, Andrea Santamato, Antonio Greco, Davide Seripa & Alberto Pilotto. (2012) Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies. Immunotherapy 4:2, pages 213-238.
Crossref
Crossref
Marina A. Lynch & Kingston H.G. Mills. (2012) Immunology meets neuroscience – Opportunities for immune intervention in neurodegenerative diseases. Brain, Behavior, and Immunity 26:1, pages 1-10.
Crossref
Crossref